Literature DB >> 2595324

Intestinal absorption of oxalate and calcium in patients with jejunoileal bypass.

M Lindsjö1, B G Danielson, B Fellström, H Lithell, S Ljunghall.   

Abstract

Jejunoileal bypass (JIB) has been widely performed for treatment of excessive obesity. Formation of calcium oxalate stones is a common side effect. Since, under physiological conditions, the intestinal absorption of calcium and that of oxalate are interrelated, intestinal oxalate and calcium absorption were measured in the present study by isotope techniques in 19 JIB patients and 20 healthy controls. The JIB patients showed pronounced hyperoxaluria and markedly increased absorption of oxalate, with a urinary excretion of 14C-oxalate of 29 +/- 19% (controls 6.2 +/- 3.7%; p less than 0.001). There was a strong correlation between the intestinal absorption and urinary excretion of oxalate in the JIB patients (r = 0.72; p less than 0.001). Furthermore, their oxalate kinetics was altered, with continued urinary excretion of 14C-oxalate for up to 48 hours. The JIB patients also had reduced calcium absorption (36 +/- 9.1% vs. 47 +/- 9.0%; p less than 0.001) and patients with malabsorption of calcium and low urinary calcium had the highest intestinal absorption and urinary excretion of oxalate. It is concluded that hyperoxaluria in JIB patients is due to a significant extent to hyperabsorption of oxalate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2595324     DOI: 10.3109/00365598909180339

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  3 in total

Review 1.  Intestinal transport of an obdurate anion: oxalate.

Authors:  Marguerite Hatch; Robert W Freel
Journal:  Urol Res       Date:  2004-11-25

2.  True fractional calcium absorption is decreased after Roux-en-Y gastric bypass surgery.

Authors:  Claudia S Riedt; Robert E Brolin; Robert M Sherrell; M Paul Field; Sue A Shapses
Journal:  Obesity (Silver Spring)       Date:  2006-11       Impact factor: 5.002

Review 3.  Oxalate-degrading microorganisms or oxalate-degrading enzymes: which is the future therapy for enzymatic dissolution of calcium-oxalate uroliths in recurrent stone disease?

Authors:  Ammon B Peck; Benjamin K Canales; Cuong Q Nguyen
Journal:  Urolithiasis       Date:  2015-12-08       Impact factor: 3.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.